by
Gus Iversen, Editor in Chief | April 24, 2026
ECRI has separated its spend management and recall management offerings into a new independent company, Staritas, supported by an investment from the Menlo Park, California-based firm Accel-KKR.
The move shifts a long-standing segment of ECRI’s operations, focused on supply chain analytics, into a stand-alone entity, while the nonprofit narrows its focus to patient safety and clinical guidance. ECRI CEO Marcus Schabacker, M.D., said the separation is intended to accelerate development of the platform and improve how healthcare organizations use supply chain data.
Staritas will continue providing analytics and benchmarking tools used by hospitals to manage purchasing decisions, supplier performance and product recalls. The company draws on data sets developed over several decades, and serves clients in more than 70 countries. According to ECRI, its tools are used by nearly 90% of large U.S. hospitals and health systems.
Ad Statistics
Times Displayed: 6679
Times Visited: 20 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Accel-KKR, which manages more than $23 billion in committed capital, is backing the new company with the expectation of expanding its technology and data capabilities. Park Durrett, managing director at Accel-KKR, said the firm plans to build on the existing platform and support product development.
The newly independent company will be led by CEO Emmet O’Gara, who said the focus will remain on helping healthcare organizations manage costs and supply chain complexity through data and analytics. Customers will continue using existing products without disruption, with additional investments planned to expand functionality.
The separation also marks a strategic shift for ECRI. The Plymouth Meeting, Pennsylvania-based organization said it will concentrate exclusively on patient safety, evidence-based medicine and healthcare system improvement. Schabacker said the organization is increasing investment in research, data assets and safety initiatives.
ECRI cited ongoing concerns about preventable harm in healthcare, noting that adverse events remain common in U.S. hospitals. The organization said the restructuring is intended to align its resources more directly with those challenges.
